Vitamin E has earned the nickname “the sex vitamin” for a reason. This powerful antioxidant protects your cells from ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

AVeta Medical, developer of the VITA AV™ platform, today announced the appointment of Karen Noblett, M.D. as CEO. Eileen Duffy, who served as interim CEO, has been appointed Chair of the Board of ...

Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi ...

Hello, dear readers! Welcome to our monthly letters column. Cold weather is here, and the annual flu season is ramping up. The dominant virus this year, H3N2, is a nasty ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) climbed about 3.5% after the company released encouraging interim results ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial ...

MRI is the ideal imaging modality for initial evaluation and diagnosis of testicular cancer.

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

At the end of October, PIP and ADP were providing financial support to 4,373,941 people. Psychiatric disorder (39% of claims) Musculoskeletal disease (general) (19% of claims) ...

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...